9543 results
Cited 545 times since 2014 (48.5 per year)
source: EuropePMC
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Volume 46, Issue 4, 29 5 2014, Pages 517-592
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, European Society of Cardiology Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, EACTS Clinical Guidelines Committee, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner
Abstract
Cited 2824 times since 2014 (251.4 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 39, 29 5 2014, Pages 2733-2779
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H
Abstract
Cited 3087 times since 2014 (274.8 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 37, 29 5 2014, Pages 2541-2619
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A
Abstract
Cited 2817 times since 2014 (250.8 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 41, 29 5 2014, Pages 2873-2926
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).
Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwöger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ, ESC Committee for Practice Guidelines
Abstract
Cited 1591 times since 2014 (141.6 per year)
source: EuropePMC
European heart journal,
Volume 35, Issue 43, 29 5 2014, Pages 3033-69, 3069a-3069k
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)
Abstract
Cited 23 times since 2014 (2 per year)
source: EuropePMC
The international journal of cardiovascular imaging,
Volume 31, Issue 1, 27 4 2014, Pages 151-161
Automatic detection and quantification of the Agatston coronary artery calcium score on contrast computed tomography angiography.
Ahmed W, de Graaf MA, Broersen A, Kitslaar PH, Oost E, Dijkstra J, Bax JJ, Reiber JH, Scholte AJ
Potentially, Agatston coronary artery calcium (CAC) score could be calculated on contrast computed tomography coronary angiography (CTA). This will make a separate non-contrast CT scan superfluous. This study aims to assess the performance of a novel fully automatic algorithm to detect and quantify the Agatston CAC score in contrast CTA images. From a clinical registry, 20 patients were randomly selected for each CAC category (i.e. 0, 1-99, 100-399, 400-999, ≥1,000). The Agatston CAC score on no...
Abstract
Cited 7 times since 2014 (0.6 per year)
source: EuropePMC
Cardiology in the young,
Volume 24 Suppl 2, 27 4 2014, Pages 3-12
Imaging the first trimester heart: ultrasound correlation with morphology.
Jansen FA, Calkoen EE, Jongbloed MR, Bartelings MM, Haak MC
First trimester sonography is a widely used technique to examine the foetus early in pregnancy. The desire to recognise complex anatomy already in early developmental stages stresses the need for a thorough knowledge of basic developmental processes as well as recognition of cardiac compartments based on their morphology. In this paper, we describe the possibilities and limitations of sonographic assessment of the foetal heart between 10 and 14 weeks of gestation and correlate this to morphology...
Abstract
Cited 9 times since 2014 (0.8 per year)
source: EuropePMC
The American journal of cardiology,
Volume 114, Issue 10, 27 4 2014, Pages 1490-1496
Determinants of right ventricular remodeling following ST-segment elevation myocardial infarction.
Hoogslag GE, Haeck ML, Velders MA, Joyce E, Boden H, Schalij MJ, Bax JJ, Ajmone Marsan N, Delgado V
Right ventricular (RV) function after ST-segment elevation myocardial infarction (STEMI) has important prognostic implications. However, the changes in RV function over time after STEMI and the incidence of RV remodeling remain unknown. The present study evaluated changes in RV dimensions and function in contemporary patients with first STEMI and assessed the independent determinants of RV dysfunction at follow-up. Patients with first STEMI (n = 940, 60 ± 11 years, 77% men) treated with primary...
Abstract
Cited 23 times since 2014 (2 per year)
source: EuropePMC
The American journal of cardiology,
Volume 114, Issue 10, 27 4 2014, Pages 1556-1561
Insights into new-onset rhythm conduction disorders detected by multi-detector row computed tomography after transcatheter aortic valve implantation.
Katsanos S, van Rosendael P, Kamperidis V, van der Kley F, Joyce E, Debonnaire P, Karalis I, Bax JJ, Marsan NA, Delgado V
New-onset rhythm conduction disorders are frequent after transcatheter aortic valve implantation (TAVI). Multidetector row computed tomography may shed light on the pathophysiology of rhythm conduction disorders in patients who undergo TAVI with the Edwards SAPIEN valve. A total of 94 patients (mean age 81 ± 7 years, 48% men) treated with TAVI with the Edwards SAPIEN valve who underwent pre- and post-TAVI multidetector row computed tomography were included. Patients with preexisting right bundle...
Abstract
Cited 153 times since 2014 (13.6 per year)
source: EuropePMC
Nature communications,
Volume 5, 27 4 2014, Pages 4747
The evolutionary origin of human hyper-cooperation.
Burkart JM, Allon O, Amici F, Fichtel C, Finkenwirth C, Heschl A, Huber J, Isler K, Kosonen ZK, Martins E, Meulman EJ, Richiger R, Rueth K, Spillmann B, Wiesendanger S, van Schaik CP
Proactive, that is, unsolicited, prosociality is a key component of our hyper-cooperation, which in turn has enabled the emergence of various uniquely human traits, including complex cognition, morality and cumulative culture and technology. However, the evolutionary foundation of the human prosocial sentiment remains poorly understood, largely because primate data from numerous, often incommensurable testing paradigms do not provide an adequate basis for formal tests of the various functional h...
Abstract
Cited 26 times since 2014 (2.3 per year)
source: EuropePMC
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Volume 46, Issue 5, 26 4 2014, Pages 831-839
Bicuspid aortic valve: phosphorylation of c-Kit and downstream targets are prognostic for future aortopathy.
Grewal N, Gittenberger-de Groot AC, DeRuiter MC, Klautz RJ, Poelmann RE, Duim S, Lindeman JH, Koenraadt WM, Jongbloed MR, Mohamed SA, Sievers HH, Bogers AJ, Goumans MJ
Objectives: The clinical course of many patients with a bicuspid aortic valve (BAV) is complicated by ascending aortic dilatation. Currently, the indication for aortic surgery is solely based on the aortic diameter and subsequently only a small proportion of BAV patients undergoing valve surgery require concomitant ascending aortic replacement based on these recommendations. Unfortunately, a substantial number of BAV patients still develop aortic dilatation in the future and would potentially be...
Abstract
Cited 68 times since 2014 (6 per year)
source: EuropePMC
FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Volume 28, Issue 12, 25 4 2014, Pages 5361-5375
Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity.
Boon MR, Kooijman S, van Dam AD, Pelgrom LR, Berbée JF, Visseren CA, van Aggele RC, van den Hoek AM, Sips HC, Lombès M, Havekes LM, Tamsma JT, Guigas B, Meijer OC, Jukema JW, Rensen PC
The endocannabinoid system is an important player in energy metabolism by regulating appetite, lipolysis, and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long-term maintenance of weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade reverses dyslipidemia in obesity has not yet been clarified. In this study, we showed that CB1R blockade with the systemic CB1R blocker rimonabant enhanced wh...
Abstract
Cited 38 times since 2014 (3.4 per year)
source: EuropePMC
Circulation. Arrhythmia and electrophysiology,
Volume 7, Issue 5, 23 4 2014, Pages 889-897
Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case series.
Kapel GF, Reichlin T, Wijnmaalen AP, Tedrow UB, Piers SR, Schalij MJ, Hazekamp MG, Jongbloed MR, Stevenson WG, Zeppenfeld K
Background: Radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in repaired Tetralogy of Fallot focuses on isthmuses in the right ventricle but may be hampered by hypertrophied myocardium or prosthetic material. These patients may benefit from ablation at the left side of the ventricular septum. Methods and results: Records from 28 consecutive repaired Tetralogy of Fallot patients from 2 centers who underwent VT ablation were reviewed. Ablation targeted anatomic isthmuses con...
Abstract
Cited 32 times since 2014 (2.8 per year)
source: EuropePMC
Transplant international : official journal of the European Society for Organ Transplantation,
Volume 27, Issue 10, 22 4 2014, Pages 994-1004
Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?
Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T
Mycophenolate mofetil (MMF) is used to prevent acute rejection following solid organ transplantation in transplant centers all over the world. Patients from different ethnic backgrounds are treated with this drug, for which therapeutic drug monitoring (TDM) has not become the standard of practice in most centers. Whether or not some ethnic groups require a different MMF dose has been a topic of debate in recent years. In this review, it is shown that Asian patients, compared with Caucasian patie...
Abstract
Cited 12 times since 2014 (1.1 per year)
source: EuropePMC
Cardiovascular and interventional radiology,
Volume 38, Issue 3, 22 4 2014, Pages 600-605
Thromboembolic complications after Zenith® Low Profile Endovascular Graft for infrarenal abdominal aneurysms.
Urlings TA, de Vries AC, de Mol van Otterloo JC, Eefting D, van der Linden E
Purpose: The purpose of this study was to objectify and evaluate risk factors for thromboembolic complications after treatment with a Zenith(®) Low Profile Endovascular Graft (Zenith LP). Results were compared with those in the recent literature on endovascular aortic repair (EVAR) and with the thromboembolic complications in the patient group treated with a Zenith Flex Endovascular Graft in our institute in the period before the use of the Zenith LP. Materials and methods: All consecutive patie...
Abstract
Cited 25 times since 2014 (2.2 per year)
source: EuropePMC
British journal of anaesthesia,
Volume 114, Issue 2, 21 3 2014, Pages 319-326
Effects of early and late diabetic neuropathy on sciatic nerve block duration and neurotoxicity in Zucker diabetic fatty rats.
Lirk P, Verhamme C, Boeckh R, Stevens MF, ten Hoope W, Gerner P, Blumenthal S, de Girolami U, van Schaik IN, Hollmann MW, Picardi S
Background: The neuropathy of type II diabetes mellitus (DM) is increasing in prevalence worldwide. We aimed to test the hypothesis that in a rodent model of type II DM, neuropathy would lead to increased neurotoxicity and block duration after lidocaine-induced sciatic nerve block when compared with control animals. Methods: Experiments were carried out in Zucker diabetic fatty rats aged 10 weeks (early diabetic) or 18 weeks (late diabetic, with or without insulin 3 units per day), and age-match...
Abstract
Cited 32 times since 2014 (2.8 per year)
source: EuropePMC
Journal of magnetic resonance imaging : JMRI,
Volume 41, Issue 6, 20 3 2014, Pages 1512-1520
Characterization and improved quantification of left ventricular inflow using streamline visualization with 4DFlow MRI in healthy controls and patients after atrioventricular septal defect correction.
Calkoen EE, Roest AA, Kroft LJ, van der Geest RJ, Jongbloed MR, van den Boogaard PJ, Blom NA, Hazekamp MG, de Roos A, Westenberg JJ
Purpose: To evaluate trans-left atrioventricular valve (LAVV) blood flow and optimize left ventricular inflow quantification in healthy controls and patients after atrioventricular septal defect (AVSD) correction. Materials and methods: Twenty-five patients after AVSD correction and 25 controls underwent 4DFlow MRI. Using streamline visualization in four- and two-chamber views, inflow direction at early and late filling was defined at the annulus level and at the peak inflow velocity (PIV) level...
Abstract
Cited 63 times since 2014 (5.6 per year)
source: EuropePMC
European heart journal,
Volume 36, Issue 1, 20 3 2014, Pages 39-48
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Kühnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, Willems van Dijk K, Rensen PC, Jukema JW, Princen HM
Background: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from atheroprotective HDL to atherogenic (V)LDL. The CETP inhibitor anacetrapib decreases (V)LDL-C by ∼15-40% and increases HDL-C by ∼40-140% in clinical trials. We evaluated the effec...
Abstract
Cited 160 times since 2014 (14.2 per year)
source: EuropePMC
Journal of lipid research,
Volume 55, Issue 10, 19 3 2014, Pages 2103-2112
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
Kühnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schäfer HL, Schwahn U, Jukema JW, Princen HM
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice received a Western-type diet and were treated with alirocumab (3 or 10 mg/kg, weekly subcutaneous dosing) alone and in combination with atorvastatin (3.6 mg/kg/d) for 18 weeks. Alirocumab alone dose-dependen...
Abstract
European heart journal. Cardiovascular Imaging,
Volume 15, Issue 12, 19 3 2014, Pages 1428
Three-dimensional transoesophageal echocardiographic visualization of malignant anomalous left main coronary origin and course causing sudden cardiac death.
Kamperidis V, Katsanos S, Bertels RA, Schalij MJ, Delgado V
Abstract
